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time course of beta activity showed more evident DBS-in-
duced changes in the chronic than in the hyperacute phase 
(p = 0.014). DBS-induced changes in STN beta LFPs in pa-
tients undergoing DBS in chronic phase provide useful infor-
mation for developing a new neurosignal-controlled adap-
tive DBS system. 
 
Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Neuronal activity around the macroelectrodes im-
planted in the human subthalamic nucleus (STN) for 
deep brain stimulation (DBS) produces oscillations 
known as local field potentials (LFPs)  [1–3] . These signals 
provided physiological information about STN responses 
to various stimuli  [4–9] .
 Over recent years, studies describing STN LFP signals 
recorded during DBS have done much to explain the 
mechanisms underlying DBS in patients with Parkin-
son’s disease (PD)  [10–16] . Studies investigating DBS-in-
duced changes in STN LFPs focused on rhythms oscillat-
ing from the low-frequency band (1–7 Hz) to the beta 
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 Abstract 
 In the past years, local field potential (LFP) signals recorded 
from the subthalamic nucleus (STN) in patients undergoing 
deep brain stimulation (DBS) for Parkinson’s disease (PD) dis-
closed that DBS has a controversial effect on STN beta oscil-
lations recorded 2–7 days after surgery for macroelectrode 
implantation. Nothing is known about these DBS-induced 
oscillatory changes 30 days after surgery. We recorded STN 
LFPs during ongoing DBS in 7 patients with PD, immediately 
(hyperacute phase) and 30 days (chronic phase) after sur-
gery. STN LFP recordings showed stationary intranuclear 
STN beta LFP activity in hyperacute and chronic phases, con-
firming that beta peaks were also present in chronic record-
ings. Power spectra of nuclei with significant beta activity 
(54% of the sample) showed that it decreased significantly 
during DBS (p = 0.021) under both recording conditions. The 
 Received: December 22, 2010 
 Accepted after revision: April 4, 2011 
 Published online: July 12, 2011 
 Alberto Priori, MD, PhD, Dipartimento di Scienze Neurologiche 
 Università degli Studi di Milano, Centro Clinico per la Neurostimolazione, 
 le Neurotecnologie ed i Disordini del Movimento, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Via F. Sforza 35, IT–20122 Milano (Italy) 
 Tel. +39 02 5503 3621, E-Mail alberto.priori   @   unimi.it 
 
 © 2011 S. Karger AG, Basel
1424–862X/11/0193–0151$38.00/0 
 Accessible online at:
www.karger.com/nsg 
D
ow
nl
oa
de
d 
by
: 
94
.1
67
.1
11
.1
2 
- 1
0/
29
/2
01
3 
3:
54
:2
9 
PM
 Rosa et al.  Neurosignals 2011;19:151–162 152
band (8–35 Hz). In particular, low-frequency STN oscil-
lations increased during ongoing STN DBS  [16] confirm-
ing previous observations that power in the 1–1.5 Hz 
band increased and slowly decayed to baseline levels after 
DBS was turned off  [15] .
 Nevertheless, DBS-induced changes in STN beta oscil-
lations remain controversial. Some investigators reported 
that after short-term and long-term STN DBS, beta oscil-
lations decreased both in the STN itself and in the globus 
pallidus internus (GPi)  [13, 17–20] . Conversely, our record-
ings soon after STN DBS  [11] and during STN DBS  [16, 21] 
failed to confirm the beta activity decrease. More recently, 
two studies reported that the beta oscillations significant-
ly decreased during DBS, but did so only in parkinsonian 
patients whose LFP recordings already showed high-beta 
activity at baseline  [10, 12] . These studies documented 
changes in STN beta LFPs in PD patients only during the 
first week after DBS macroelectrode implantation.
 A subsequent study then investigated the time-depen-
dent STN LFP changes after DBS surgery in PD, and pro-
vided new evidence showing that DBS macroelectrode 
impedance and STN LFP patterns are a function of the 
time elapsing between macroelectrode implantation and 
LFP recording  [22] . The time course of macroelectrode 
impedance is related to changes in the electrode/tissue 
interface and in the STN LFP low-frequency activity. 
Conversely, macroelectrode impedance is unrelated to 
beta activity, hence beta power recorded 30 days after sur-
gery for macroelectrode positioning (chronic condition) 
is similar to power recorded 2–7 days thereafter  [22] .
 None investigated how DBS changes the STN LFP be-
ta activity in the longer term. Having this information 
would be useful for developing new adaptive DBS systems 
based on STN-LFP signal feedback designed to adapt 
DBS parameters to individual patient’s clinical state. 
 In this paper, to clarify how DBS acts in the long term, 
we investigated changes induced by DBS in STN beta LFP 
in patients with PD 30 days after macroelectrode implan-
tation. To do so, we recorded STN LFPs in 7 patients with 
PD during ongoing DBS immediately (hyperacute phase) 
and 30 days (chronic phase) after surgery.
 Patients and Methods 
 Patients 
 Seven patients (6 men) with idiopathic PD and fulfilling the 
specific inclusion criteria for DBS treatment were studied after 
their informed consent and local institutional review board ap-
proval  [23] . The study conformed with the Declaration of Helsin-
ki. All the patients, except one, were bilaterally implanted in the 
STN with DBS macroelectrodes at the Functional Neurosurgery 
Unit of the Institute Galeazzi IRCCS in Milan, Italy. The other pa-
tient was studied during unilateral re-implantation of DBS mac-
roelectrodes in the STN (patient 5 in  table 1 ). Clinical details, in-
cluding pre-surgery assessment of the Unified Parkinson’s Disease 
Rating Scale III (UPDRS III, motor part), are reported in  table 1 .
 Surgical Procedures  
 Surgical procedures are reported elsewhere  [22] . In brief, the 
procedure for DBS consisted of a first surgery for macroelectrode 
placement in the STN followed by a second surgery to implant the 
subcutaneous pulse generator  [24] .
 Between the two operations, macroelectrodes were not con-
nected to the stimulator and were accessible for neurophysiologi-
cal recordings. In our protocol, LFPs were first recorded from 
implanted macroelectrodes immediately at the end of the first 
surgery, when the patient was still in the operating room (hyper-
acute phase). Then, to enable LFP recordings during DBS in the 
longer term we postponed the pulse generator implant, 30 days 
after macroelectrodes positioning  [22] . After the first operation, 
the implanted macroelectrodes were left under the skin so that the 
patient could be safely discharged. The stimulator was not im-
planted and the patient did not receive DBS during this time. 
About 30 days later, patients were again hospitalized and under-
Table 1. P atients’ clinical details
Patient Age
years
Gender Years of
disease
Predominant 
motor symptoms
UPDRS III scores 
pre-surgery 
ON/OFF levodopa
1 71 M 5 Rigidity 30/44
2 70 M 7 Tremor, dyskinesias 19/42
3 69 M 10 Tremor 12/31
4 59 M 5 Tremor 18/35
5 58 M 13 Tremor, freezing, dyskinesias 18/34
6 72 M 10 Rigidity, tremor 21/40
7 69 F 5 Tremor, rigidity, dyskinesias 20/38
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went surgery to implant the subcutaneous pulse generator. Before 
the operation, the macroelectrodes were externalized to allow 
LFP recordings during DBS 30 days after the first surgery (chron-
ic phase).
 The implanted 3389 Medtronic macroelectrode had four
cylindrical contacts (diameter 1.27 mm, length 1.5 mm, placed
2 mm apart center-to-center) denominated 0–1–2–3, beginning 
from the more caudal contact. The STN was targeted by visualiza-
tion through a CT-MRI fusion-based technique before surgery 
 [25] . The site of macroelectrode implantation was adjusted during 
surgery with micro-recordings and by clinically assessing chang-
es induced by stimulation through the microelectrodes and 
through the implanted macroelectrodes. For all nuclei studied, 
postoperative MRI was obtained to assess the accuracy of final 
position of DBS macroelectrodes and to verify the placement of 
contact 0 within the STN  [24] ( table 2 ).
 Experimental Protocol and LFP Recordings 
 LFP activity was recorded in two experimental sessions: hy-
peracute phase (t-0h) and chronic phase (t-30d) ( fig. 1 ). All pa-
tients were studied at least 8 h after withdrawal from antiparkin-
sonian medication (off levodopa).
 Each experimental session lasted approximately 30 min and 
took place in the operating room with the following steps: (1) eval-
uation of the impedance of each macroelectrodes’ contact pair; (2) 
stimulation threshold: clinical assessment of optimal stimulation 
intensity followed by a pause for rest; (3) baseline: LFP recording 
at rest for about 2 min; (4) DBS on: LFP recording during high-
frequency stimulation for about 6 min, and (5) DBS off: LFP re-
cording after high-frequency stimulation for about 2 min.
 Recording contact pairs and stimulation intensity were select-
ed during the first recording session (hyperacute phase) and used 
also to record LFPs in the second session (chronic phase). Of the 
7 participants, 6 underwent the recording procedures for the im-
planted macroelectrodes on both sides (right side first) and 1 pa-
tient for the re-implanted macroelectrode side (right side).
 Macroelectrode impedance was evaluated through an imped-
ance meter at 30 Hz (Model EZM 4; Grass, USA). Impedance was 
evaluated on all contact pairs (0–1, 0–2, 0–3, 1–2, 1–3 and 2–3). 
The contact pair (0–2 or 1–3) showing the highest impedance val-
ue was selected for the bipolar recording, leaving the central con-
tact (1 or 2) free for delivering DBS. LFPs were recorded through 
the FilterDBS system for artifact-free recording  [21] . Two stan-
dard skin Ag/AgCl electrodes (RedDot; 3M, USA) placed on the 
left and on the right supraclavicular area were used as recording 
and stimulation references respectively  [16] . For electrical stimu-
lation we used a constant voltage stimulator (Dual Screen; 
Medtronic, Minneapolis, Minn., USA) and DBS was delivered 
with a pulse width of 60   s and frequency of 130 Hz at a previ-
ously tested optimal stimulation intensity. Optimal stimulation 
intensity was set according to the stimulation threshold repre-
sented by the highest stimulation intensity that induced therapeu-
tic effects without side effects. The threshold for each nucleus was 
established by a neurologist during the first recording session.
 The recorded signals were amplified (50,000 ! ) and filtered 
(0.5–45 Hz) through the FilterDBS, then digitized through the 
Table 2.  Patients’ electrode position and recording configuration
Patient Recording side Target coordinates, mm Recording 
contact pair
Impedance 
K
Stimulation 
contact
Stimulation
intensity, V 
t-0h t-30d X Y Z t-0h t-30d t-0h t-30d t-0h t-30d t-0h t-30d
1 Right
Left
12.7
12.7
3.8
4
5
3.5
02
02
9.3
17.2
12.9
10.5
        1
        1
       2.5
       2.5
2 Right 12.5 3.5 3.6 13 18.1 10.1         2        2.5
Left 11.5 3.6 3.1 02 24.3 7         1        2
3 Right 13.2 3 4.1 02 10.1 7.5         1        2.5
Left 12.8 2.8 3.8 02 13.2 10.5         1        3
4 Right 10.7 3.5 3.9 13 10.1 7         2        3.5
Left 11 3.8 4.1 13 17.5 8.1         2        3.5
5 Left 11 4 4 13 12.6 11.2         2        2
6 Right 11.7 4 5.9 13 16.1 10.4         2        3.5
Left 10.7 3 3.9 13 18.2 10.5         2        3.5
7 Right 12 3.8 2.2 13 13.6 6.5         2        3
Left 14.1 3.8 2.1 13 20.8 10.5         2        3
Ta rget coordinates related to final position of contact 0. Target coordinates were accorded to the anterior commissural-posterior 
commissural (AC–PC) line and midcommissural point (MCP). X = Lateral from midline; Y = posterior from MCP; Z = ventral to AC–
PC line.
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USB-6251 multifunctional device with 8 inputs (National In-
struments Corp., Austin, Tex., USA) at 500 sample/s and 16-bit 
resolution with 10 V range. Recorded signals were displayed on-
line on a PC monitor with LabVIEW Signal Express software 
(version 2.5; National Instruments Corp.) and stored for off-line 
analysis.
 Data Analysis 
 Data were analyzed off-line with Matlab software (version 
7.10; The MathWorks, Natick, Mass., USA). Signals were prelimi-
narily band-passed (2–45 Hz) with a Finite Impulse Response fil-
ter and resampled at 125 Hz. Signals containing noise were dis-
carded after visual inspection.
 The oscillatory activity recorded from the STN was quantified 
in the frequency domain by analyzing power spectral density 
(PSD) for the recorded LFPs in the two phases (hyperacute and 
chronic), using a non-parametric approach based on the discrete 
Fourier transform (DFT). More specifically, spectra were calcu-
lated using Welch’s averaged, modified periodogram  [26] . A Han-
ning window  W(j) was applied to divide the signal, containing n 
samples, into K segments and for each segment the modified peri-
odogram  I k was calculated from the DFT coefficients  A k (n) . Each 
segment was 128 samples in length (L = 128), to obtain a frequen-
cy resolution of 0.98 Hz. 
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 The PSD of each signal was obtained by averaging the periodo-
gram  I k calculated in each segment.
 To test whether DBS influenced LFP activity at both t-0h and 
t-30d, we considered three states of interest: baseline (1 min pre-
DBS), DBS on (1 min after DBS was turned on), and DBS off
(1 min after DBS was turned off).
 To account for the high inter-nuclei variability, PSD in each 
nucleus was normalized by the total spectral power in the 2–45 
Hz frequency range during the baseline condition in hyperacute 
phase according to the following formula: 
	 
 	 
45
2
N
f
PSD f
PSD f


 PSDbaseline t-0h (f)
 where PSD N is the normalized PSD, and f is the frequency. 
 LFP analysis focused on the beta frequency band detected in 
each phase for each nucleus as follows. Beta band was analyzed 
estimating the spectral power, calculated as: 
	 
B
f B
SP PSD f


 where B is the beta band (see Identifying the Beta Band) and  SP B 
is the spectral power. 
 In addition, to detect the time course of beta modulation 
throughout the whole experimental session, and to compare it 
with baseline, data were analyzed with a time-frequency approach 
(short-time Fourier transform, STFT). In each LFP recording, a 
time-moving Hanning window, 2.05 s long, was applied to the sig-
nal: the window was moved forward 1.02 s obtaining a recording 
segment 2.05 s long every 1.02 s advance and each segment over-
lapped the previous segment by 1.02 s. The resulting time-frequen-
cy spectrum was calculated in each 2.05 s segment, with a final 
time resolution of 1.02 s and a frequency resolution of 0.49 Hz. 
 Beta time course was determined from the time-frequency 
spectrum by calculating the integral in time of the specific beta 
band for each nucleus. Beta time course was studied as percentage 
power changes from baseline recording that was calculated as 
mean value of power during the 2 min before turning the DBS on. 
Surgical
procedure Electrode
implant
Stimulator
implant
LFP
recording Hyperacute phase Chronic phase
0
DBS
0
Baseline Baseline
2 8 10 Time (min) 0 2 8 10 Time (min)
OFF OFF OFF OFFON ONDBS
30 Time (days)
 Fig. 1. Surgical procedure and experimental protocol. Timeline of 
deep brain stimulation (DBS) surgical procedure and local field 
potential (LFP) recordings for the experimental protocol. The 
pulse generator was placed and connected to macroelectrode 30 
days after macroelectrode positioning. LFPs were recorded at two 
time points after macroelectrode implantation: the hyperacute 
phase (immediately after surgery, t-0h) and the chronic phase (30 
days after surgery, t-30d). The gray arrow represents time (days). 
The lower panel shows the three LFP recording conditions: before 
stimulation (baseline, 2 min), during stimulation (DBS on, 6 min) 
and after stimulation (DBS off, 2 min). The black line represents 
time (min).  
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To analyze the beta time course (excluding the baseline) during 
the conditions DBS on and DBS off, we subdivided the time re-
cording in consecutive segments 30 s long starting from 0, yield-
ing 12 segments in the DBS on condition (from ON1 to ON12) and 
4 segments in the DBS off condition (from OFF1 to OFF4). We 
also compared mean value for segments in the hyperacute and 
chronic phases.
 Identifying the Beta Band 
 Each nucleus was characterized to detect the beta range and 
its corresponding peak. To do so, the mean and standard devia-
tion (SD) of PSD in the 8–45 Hz band in each nucleus were con-
sidered to obtain the threshold for significant spectral bands in 
the hyperacute and chronic phases (95% confidence interval (CI): 
mean  8 1.97 SD). The beta activity was considered significant if 
PSD values in the 8–30 Hz range exceeded the threshold. If the 
beta activity was significant, we defined the maximum PSD value 
within the 8–30 Hz range as the beta peak. We then considered 
the frequency band ranging  8 4 Hz around the beta peak for sub-
sequent analyses. If beta activity was not significant we consid-
ered a standard beta frequency range. The individual beta band 
was classified as low-beta band if the beta peak found belonged to 
the 8–20 Hz band and as high-beta band if the peak found be-
longed to the 21–30 Hz band. To account for the inter-nuclei vari-
ability, the spectral power in the beta band was normalized by the 
length of the beta band in the corresponding phase.
 Statistical Analysis 
 To evaluate the effect of time on macroelectrode impedance, a 
two-tailed paired Student t test was used to compare all values for 
the contact pairs of macroelecrode used for recording in hyper-
acute and chronic phases. To assess the dependency of beta on the 
impedance, Pearson’s linear correlation coefficient (GraphPad 
Prism 3.0) was calculated (p  ! 0.05) between impedance values in 
both phases and individual beta powers.
 Two-tailed paired Student’s t test was also used to evaluate the 
effect of time on central frequency of the beta peak: values were 
compared in the hyperacute and chronic phases.
 To evaluate the correlation between nuclei with significant 
beta band activity and the contact pairs used for recording, we 
performed a Pearson’s   2 test. A one-way repeated measures anal-
ysis of variance (ANOVA) (STATISTICA 5.5; StatSoft Inc.) was 
used to test differences between each target coordinate of macro-
electrodes (X, Y, Z) ( table 2 ) in nuclei with and without significant 
beta band activity with factor ‘beta band’ (2 levels: presence, ab-
sence). To study the effect of DBS on LFP activity, data were ana-
lyzed for the whole population and considering only the nuclei 
with significant beta band activity. A two-way ANOVA for beta 
spectral power was run with factors ‘stimulation state’ (within 
factor, 3 levels: baseline, DBS on, DBS off) and ‘recording phase’ 
(within factor, 2 levels: hyperacute and chronic). Tukey honest 
significant test was used for post hoc analysis; differences were 
considered significant at p  ! 0.05.
 To analyze the statistical significance of data for nuclei with a 
significant beta band and to evaluate the effect of stimulation over 
time, we tested the percentage power changes in beta power 
through change point analysis with a percentage time resolution 
of 3.3%  [27] . Change was significant at a 95% confidence level
(p  ! 0.05). The time course of beta activity in the hyperacute and 
chronic phases was compared in DBS on and DBS off conditions. 
To study the DBS on condition a two-way ANOVA with factor 
‘time’ (within factor, DBS on: 12 levels from ON1 to ON12) and 
Table 3.  Nuclei characterization during ongoing DBS in the 7 patients with PD
Patient Recording side     Beta Frequency peak DBS ON D BS OFF
t-0h t-30d     t-0h   t-30d t-0h t-30d t-0h t-30d t- 0h t-30d
2 Right   ! ! 17 15 ff ff dd dd
4 Right   ! ! 15 13 f ff d dd
4 Left   ! ! 9 11 ff f dd d
6 Right   ! ! 12 11 f nd d nd
6 Left   ! ! 10 17 f ff d d
7 Right   ! ! 11 14 f f d d
7 Left   ! ! 13 12 f f d d
1 Right     –   – – – d dd f ff
1 Left     –   – – – nd nd nd nd
2 Left     –   – – – dd dd ff f
3 Right     –   – – – f d d d
3 Left     –   – – – dd dd f f
5 Right     –   – – – f nd d nd
! = Significant beta band found; nd = not defined because signals contained noise. Arrows within DBS ON 
column indicate the qualitative increase or decrease of beta band in each nucleus compared with baseline
(f decrease of beta band <50% compared to baseline; f f decrease of beta band ≥50% compared to baseline;
d increase of beta band <50% compared to baseline; d d increase of beta band ≥50% compared to baseline);
arrows within DBS OFF column indicate the increase or decrease compared with DBS ON.
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factor ‘recording phase’ (within factor, 2 levels: hyperacute and 
chronic) was used. To study the DBS off condition we used a two-
way ANOVA with factor ‘time’ (within factor, DBS off: 4 levels 
from OFF1 to OFF4) and factor ’recording phase’ (within factor, 
2 levels: hyperacute and chronic). Tukey honest significant test 
was used for post hoc analysis; differences were considered sig-
nificant at p  ! 0.05.
 Results 
 Confirming previous results  [22] , in all 7 patients mac-
roelectrode impedance changed significantly over time 
(mean  8 SD; t-0h vs. t-30d: 15.33  8 4.59 vs. 9.15  8 1.97 
K  , p = 0.005) ( table  2 ). Correlation analysis between 
 Fig. 2. Spectral analysis.  a Hyperacute (t-0h) and chronic (t-30d) 
phases for whole population: grand average for whole population 
(n = 10 nuclei) of the power spectral density (PSD) of beta band
in the three experimental conditions: pre-stimulation (baseline; 
–––––––– ), during stimulation (DBS on; ––––––) and after stimu-
lation (DBS off; –·–·–·–·–) in the t-0h phase on the left and in the 
t-30d phase on the right. Each PSD was normalized by the total 
spectral power in the 2–45 Hz frequency range of hyperacute 
baseline. Beta band PSD was aligned on beta peak of each nucleus 
(0 Hz); if peak was not found, PSD was aligned on central value of 
standard low-beta band (9–21 Hz). On the y-axis the normalized 
PSD (arbitrary units (AU), logarithmic scale) and on the x-axis the 
frequency (Hz, linear scale).  b t-0h and t-30d phases for nuclei 
with significant beta band: grand average for nuclei with signifi-
cant beta band (n = 6 nuclei) of PSD of beta band in the three ex-
perimental conditions: pre-stimulation (baseline; –––––––– ), dur-
ing stimulation (DBS on;  ––––––) and after stimulation (DBS off; 
–·–·–·–·–) in the t-0h and in the t-30d phases. The plot is organized 
as in  a . The histogram represents beta power for nuclei with sig-
nificant beta band in the t-0h and the t-30d phases grouped to-
gether for each condition (black = baseline; gray = DBS on; light 
gray = DBS off). Error bars represent the standard deviation (SD). 
On the y-axis the normalized power of beta band (AU) and on the 
x-axis the three conditions.  *  p  ! 0.05, post hoc two-way repeated 
measures analysis of variance (ANOVA). Note that beta band 
power decreases in on DBS condition both in hyperacute and 
chronic phases for nuclei with significant beta band. 
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macroelectrode impedances and power showed that beta 
power was independent from impedance values  [22] .
 Of the 13 STN nuclei studied, 7 had a significant beta 
activity at baseline (54% of sample) that was character-
ized by a beta peak belonging to the low-beta range (8–20 
Hz;  table 3 ).
 Recordings from each nucleus during the t-0h and t-
30d phases showed no significant beta peak frequency 
differences in time (t-0h vs. t-30d: 12.37  8 2.61 vs. 13.00 
 8 2.20 Hz) ( table 3 ). 
 Pearson’s   2 test revealed that a significant correlation 
between nuclei with significant beta band activity and 
contact pairs used for recording existed: in particular, 
LFPs of nuclei that showed a significant beta band were 
recorded from contact pairs 13 (  2 = 9.47, p = 0.023). Tar-
get coordinates of electrodes in nuclei with significant 
beta band activity did not differ from coordinates of elec-
trodes in nuclei without significant beta band activity.
 Owing to artifacts due to electrical devices of the op-
erating room, we excluded three nuclei from the analysis 
( table 3 ). The subsequent analysis was conducted on a to-
tal of 10 nuclei, of which 6 showed a significant beta peak. 
Data for the whole population (n = 10 nuclei) failed to find 
significant changes in beta spectral power during DBS at 
t-0h and t-30d ( fig. 2 a). Conversely, power spectra for nu-
clei with significant beta band activity (n = 6 nuclei) 
showed significant changes in beta activity during DBS 
in both recording phases ( fig.  2 b). Two-way repeated 
measures ANOVA disclosed a significant effect of the 
factor ‘stimulation state’ (p = 0.016), whereas no effects 
either of the factor ‘recording phase’ or of the interaction 
between the two factors was found. Post hoc analysis for 
the factor ‘stimulation state’ showed that beta band pow-
er significantly decreased during stimulation (p = 0.021) 
and significantly increased when DBS was turned off
(p = 0.037) returning to baseline value ( fig. 2 b).
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 Fig. 3. Time-frequency plots of beta power in a single representa-
tive nucleus. Subthalamic nucleus-local field potential (STN-LFP) 
time varying power spectrum in the beta band of right nucleus of 
patient 2.  a Time-frequency plot over the entire experimental in 
hyperacute phase (t-0h). The black dashed lines, from the left, cor-
respond to turning DBS on and to turning DBS off, respectively. 
Temporal resolution: 1.02 s; frequency resolution: 0.46 Hz. On the 
y-axis the frequency of LFP oscillations in the beta range (10–25 
Hz, log scale) and on x-axis the time (seconds, linear scale). Oscil-
lation power is color-coded on the bar on the right (red: high pow-
er; blue: low power).  b Time-frequency plot over the entire ex-
periment in chronic phase (t-30d). The plot is organized as in  a . 
Note that beta band power decreased more prominently in chron-
ic phase than in the hyperacute phase. 
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 Figure 3 represents a case of beta time course during 
the two experimental sessions (t-0h, t-30d).
 In the analysis focusing on nuclei with a significant 
beta band at baseline, averaged data in the t-0h and t-30d 
phases showed significant beta desynchronization when 
DBS was turned on. In t-0h, change-point analysis de-
tected a significant beta band decrease (from –7.96 to 
–20.16% from baseline, confidence level = 100%) after 
2.44 min while DBS was turned on. When DBS was 
turned off, beta band power immediately increased (from 
–20.16 to 3.09% from baseline, confidence level = 100%) 
( fig.  4 a). Similarly, in t-30d, when DBS was turned on, 
beta power immediately decreased (from 18.06 to –29.32% 
from baseline, confidence level = 100%) and when DBS 
was turned off increased (from –29.32 to 3.88% from 
baseline, confidence level = 99%) ( fig. 4 b).
 The time course of beta activity during DBS on condi-
tion differed significantly between t-0h and t-30d (ANO-
VA, interaction ‘time’  ! ‘recording phase’ p = 0.014). Post 
hoc analysis showed more significant beta activity chang-
es from baseline in the t-30d phase than in the t-0h phase 
in the first segment: ON1 (t-0h vs. t-30d: –7.59  8 3.36 vs. 
–42.53  8 9.08%, p = 0.0003). Conversely, ANOVA failed 
to find changes in DBS off condition beta activity be-
tween the hyperacute and chronic phases ( fig. 4 c).
 Discussion 
 Our results showed a stationary intra-nuclear STN 
beta band LFP activity in recordings obtained immedi-
ately after DBS surgery (hyperacute phase) and 30 days 
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 Fig. 4. Time course of beta activity. Beta power modulation during 
experimental session in hyperacute (t-0h) and chronic phases (t-
30d).  a Grand average (n = 6 nuclei) of the beta activity expressed 
as percentage power change from the baseline in the t-0h phase. 
On the y-axis are represented beta power (%) and on x-axis the 
time (min). Gray area represents a significant beta power change 
(p  ! 0.05).  b Grand average (n = 6 nuclei) of the beta activity ex-
pressed as percentage power change from the baseline in the t-30d 
phase. The plot is organized as in  a .  c Grand average (n = 6 nuclei) 
of the beta activity expressed as percentage power change from 
the baseline in the t-0h phase (black) and t-30d phase (dark gray). 
The gray vertical lines, from the left, correspond to the 12 seg-
ments of DBS on condition (ON1 to ON12) and the 4 segments of 
DBS off condition (OFF1 to OFF4) respectively. The plot is orga-
nized as in  a . The gray area represents the significant difference 
between hyperacute and chronic beta activity (p  ! 0.05). Note that 
both averaged data in hyperacute and chronic phases showed sig-
nificant beta desynchronization when DBS was turned on and 
beta change was significantly higher in chronic than in the hyper-
acute phase in the first segment. 
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after surgery (chronic phase) confirming that beta power 
peaks maintain at long-term recording. Although only in 
nuclei showing a prominent beta activity at baseline (54% 
of sample), STN DBS markedly reduced beta LFP oscilla-
tions during both hyperacute and chronic phases, it in-
duced the greatest reduction during chronic phase. The 
new evidence we provided describing STN DBS induced 
changes in STN beta LFPs during DBS in chronic phase 
offers essential information needed to develop a new 
adaptive DBS system.
 Because LFP beta oscillations varied widely among the 
studied STN nuclei, beta activity exceeded threshold val-
ues in only in 7 of the 13 STN nuclei studied (54%). This 
finding agrees with previous data reporting similar beta 
variability within the population studied (67 and 68%) 
 [10, 12] . The slight difference in our population was like-
ly due to a gender effect (6 men and 1 woman) given that 
beta band power is lower in males.
 The beta activity observed was then characterized de-
fining the highest peak within the band, in order to iden-
tify a possible marker of DBS action. We observed that, if 
the beta activity was significant, the highest oscillation 
was in the low-beta band and was then disrupted by DBS. 
In our sample, the significant beta activity was never 
characterized by a high-beta peak. This finding is in line 
with previous studies suggesting that, in the off medica-
tion state, the high-beta peak was shown to be lower than 
and non-linearly dependent on the low-beta peak  [28] . 
Hence, because levodopa and DBS specifically act on the 
low-beta activity, our results support the hypothesis that 
the low-beta rhythm can be considered as a marker of 
pathology whereas the high-beta rhythm can be essen-
tially a physiological rhythm  [3, 5, 28] .
 Nuclei characterization therefore showed stationary in-
tra-nuclear beta activity from the hyperacute to the chron-
ic recording phase (7 nuclei had a significant beta peak at 
baseline under both experimental phases and 6 nuclei did 
not have a beta peak in both phases). This marked station-
arity in intra-nuclear beta band activity suggests that, at 
least in a fraction of nuclei, a specific rhythm exists and 
may be a parkinsonian patient’s ‘signature’. Various studies 
have shown abnormal synchronized oscillatory activity in 
the STN and internal segment of the globus pallidus (GPi) 
of MPTP-lesioned non-human primates and patients with 
PD, showing that it is further related to symptoms of illness 
and is an important feature of PD  [1, 2, 8, 19, 29–36] , in-
cluding the abnormal beta activity  [10, 37–40] .
 Given that we found no correlation between beta pow-
er and recording macroelectrode impedance, we con-
firmed previous evidence  [22] that macroelectrode im-
pedance changes occurring between the two recording 
phases have no effect on beta band power stationarity. An 
interesting finding that confirms current knowledge on 
beta activity was that LFP from nuclei having a significant 
beta peak were all recorded bilaterally from the uppermost 
contacts (1–3). This finding fits in with previous observa-
tions that beta activity in the LFP tends to be greater in the 
dorsolateral than in ventromedial STN  [41, 42] . Consider-
ing the STN target for PD, the dorsolateral portion could 
be the most effective area of STN that seems to be involved 
in sensorimotor circuits  [43–45] . The most effective elec-
trode contact lies in the upper part of the STN intraopera-
tive recording area (near the dorsal border) confirming 
that this region has a key role in the clinical effectiveness 
of the STN DBS  [44, 46, 47] . A recent study showed a cor-
relation between the depth where the beta activity record-
ed intraoperatively was highest (local beta generator) and 
the depth of the contact independently chosen for chronic 
DBS  [48] . Hence, if we think that a local beta generator ex-
ists, then nuclei having low-beta activity could be far from 
the beta generator, whereas nuclei with a significant beta 
peak could be close to the beta generator. Notwithstand-
ing this possibility, some investigators noted that although 
the electrode position failed to limit the beneficial effect 
of chronic DBS, adjusting the stimulation intensity yield-
ed benefits in all patients  [49] . In particular, if the depth 
of contact for chronic DBS is far from depth of beta gen-
erator, more voltage has to be delivered  [48] . Since we used 
the same recording contacts in the hyperacute and chron-
ic phases, the recording coordinates remained constant, 
thus supporting the stationary beta activity.
 The previous considerations are valid for the nuclei in 
which beta activity is evident. There is a percentage of 
nuclei in which this activity is not evident independently 
from the position of the macroelectrodes  [10] . Since the 
clinical effects of DBS in patients with a marked beta ac-
tivity is not different from the one observed in subjects 
that do not have this characteristic, only in some patients 
beta activity can be considered one of the reliable marker 
of PD. Other bands may represent a possible marker in 
other patients. Previous literature showed low-frequency 
LFP modulations after drug administration  [3, 28] and 
during STN stimulation  [16] . The authors found that 
these changes were correlated with the parkinsonian pa-
tients’ clinical features.
 Our study leaves open the question how STN DBS acts 
on the various STN nuclei in patients with PD. When we 
turned DBS on, STN LFP beta oscillations decreased only 
in those nuclei with higher beta activity at baseline and 
when we turned DBS off, the DBS-induced beta band 
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suppression disappeared and the activity patterns record-
ed at baseline returned  [5, 10] . In a previous study con-
ducted in our laboratory, considering the whole pop-
ulation, we failed to show significant LFP beta power
suppression during DBS  [16] , presumably because not all 
recordings had abnormal peaks in the beta band before 
DBS and because some patients were on dopaminergic 
medication, a condition known to decrease beta activity. 
More recent studies reported that the beta oscillations de-
creased significantly during DBS but did so only in pa-
tients whose LFP recordings already showed high-beta 
activity at baseline  [10, 12] .
 A distinctive point in this study is that whereas previ-
ous studies investigated the neurophysiologic effects of 
STN DBS within days after macroelectrode implantation, 
we studied them also in patients with PD undergoing 
DBS 30 days later. We found that in nuclei with high-be-
ta activity at baseline, DBS reduced beta activity imme-
diately after surgery and 30 days later. This finding sug-
gests that the results of LFP recordings obtained in the 
hyperacute phase could be extended to the chronic phase 
although DBS markedly reduced STN beta LFPs in the 
chronic phase. Trauma from macroelectrode penetration 
causes a micro-subthalamotomic effect that transiently 
mimics the levodopa-induced effect  [3] and is accompa-
nied by a transient hyperacute improvement in parkinso-
nian motor symptoms  [50] . In agreement with this hy-
pothesis that takes into account possible changes in the 
STN networks due to plasticity mechanisms after macro-
electrode implantation, the greater beta reduction we ob-
served in the chronic phase could reflect the re-estab-
lished pathological pattern.
 Our finding that the DBS-induced local beta activity 
suppression, when present, remained stable in time, rais-
es the possibility that the reduced beta activity underlies 
some of the therapeutic actions of DBS  [10, 12, 40] . Some 
studies suggest that STN DBS could produce its clinical 
benefits by disrupting pathological oscillations at beta or 
lower frequencies also in the GPi  [18, 51] as well as in the 
substantia nigra pars reticulata (SNr)  [52, 53] . Besides, 
since striatal dopamine release during high-frequency 
stimulation has been observed  [54, 55] , we could hypoth-
esize that disrupting pathological oscillation effect could 
mimic the disruption of beta pathological oscillation in-
duced by levodopa as seen in previous studies  [3, 12, 28] . 
Moreover, STN DBS could produce its clinical effects by 
artificially mimicking the pacing action of the 300-Hz 
subthalamic rhythm which is lost in PD  [56, 57] . In neu-
rophysiological study, STN DBS activated not only the 
STN and its direct efferents but also the thalamus, the 
basal ganglia, the somatosensory cortex, the motor cor-
tex, and the supplementary motor area as disclosed also 
by functional imaging  [58, 59] . DBS generates efferent 
output transmitted to non-stimulated nuclei, supporting 
the hypothesis that STN-DBS acts in the entire cortex-
basal ganglia-cortex network  [13, 18, 60–62] .
 Our study describing neurosignals also provides the 
essential information we need for developing a new adap-
tive DBS system  [14, 16, 21, 22] . Because STN LFPs can be 
directly recorded from the implanted macroelectrodes 
also 30 days after surgery, STN oscillatory activity could 
be used in a novel closed-loop DBS system able to change 
stimulation variables automatically adapting them to the 
patient’s clinical state  [12, 14] . The idea of controlling 
DBS online through LFPs implies the identification of 
robust variables able to describe patient’s pathophysio-
logical state and the DBS-induced changes in the STN 
LFP activity. Our study provides direct evidence that in 
selected patients with PD, STN beta activity could be a 
robust variable due to its stability and its DBS induced 
reduction in the hyperacute and chronic phases to reflect 
the patient’s clinical status. What remains unclear is the 
possible correlation between beta band activity in pa-
tients undergoing DBS in chronic phase and the specific 
motor symptoms of PD. Since only a portion of our pop-
ulation showed a significant beta activity, we believe that 
other frequency bands, such as low-frequency band, 
could be used as variables of PD to adapt the stimulation 
parameters.
 Acknowledgments 
 This study was supported by the ERANET-Neuron Grant 
‘PhysiolDBS’ (Neuron-48-013), by Fondazione IRCCS Ca’ Gran-
da, Ospedale Maggiore Policlinico (Milan, Italy), Università de-
gli Studi di Milano (Italy), Ministero della Sanità (Italy), Minis-
tero dell’Università e della Ricerca Scientifica e Tecnologica (Ita-
ly).
 Disclosure Statement 
 Sara Marceglia, Sergio Barbieri and Alberto Priori are stake-
holders of Newronika SrL, a spin-off company of the Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan and 
of the Università degli Studi di Milano.
 
D
ow
nl
oa
de
d 
by
: 
94
.1
67
.1
11
.1
2 
- 1
0/
29
/2
01
3 
3:
54
:2
9 
PM
 Hyperacute and Chronic STN LFP 
Recordings during DBS 
 Neurosignals 2011;19:151–162 161
 References 
 1 Brown P: Oscillatory nature of human basal 
ganglia activity: relationship to the patho-
physiology of Parkinson’s disease. Mov Dis-
ord 2003; 18: 357–363. 
 2 Levy R, Hutchison WD, Lozano AM, Dost-
rovsky JO: Synchronized neuronal discharge 
in the basal ganglia of parkinsonian patients 
is limited to oscillatory activity. J Neurosci 
2002; 22: 2855–2861. 
 3 Priori A, Foffani G, Pesenti A, Tamma F,
Bianchi AM, Pellegrini M, Locatelli M, Mox-
on KA, Villani RM: Rhythm-specific phar-
macological modulation of subthalamic ac-
tivity in Parkinson’s disease. Exp Neurol 
2004; 189: 369–379. 
 4 Brucke C, Kupsch A, Schneider GH, Hariz 
MI, Nuttin B, Kopp U, Kempf F, Trottenberg 
T, Doyle L, Chen CC, Yarrow K, Brown P, 
Kuhn AA: The subthalamic region is activat-
ed during valence-related emotional pro-
cessing in patients with Parkinson’s disease. 
Eur J Neurosci 2007; 26: 767–774. 
 5 Foffani G, Bianchi AM, Baselli G, Priori A: 
Movement-related frequency modulation of 
beta oscillatory activity in the human sub-
thalamic nucleus. J Physiol 2005; 568: 699–
711. 
 6 Kuhn AA, Doyle L, Pogosyan A, Yarrow K, 
Kupsch A, Schneider GH, Hariz MI, Trotten-
berg T, Brown P: Modulation of beta oscilla-
tions in the subthalamic area during motor 
imagery in Parkinson’s disease. Brain 2006; 
 129: 695–706. 
 7 Kuhn AA, Hariz MI, Silberstein P, Tisch S, 
Kupsch A, Schneider GH, Limousin-Dowsey 
P, Yarrow K, Brown P: Activation of the sub-
thalamic region during emotional process-
ing in Parkinson disease. Neurology 2005; 
 65: 707–713. 
 8 Levy R, Ashby P, Hutchison WD, Lang AE, 
Lozano AM, Dostrovsky JO: Dependence of 
subthalamic nucleus oscillations on move-
ment and dopamine in Parkinson’s disease. 
Brain 2002; 125: 1196–1209. 
 9 Marceglia S, Fiorio M, Foffani G, Mrakic-
Sposta S, Tiriticco M, Locatelli M, Caputo E, 
Tinazzi M, Priori A: Modulation of beta os-
cillations in the subthalamic area during
action observation in Parkinson’s disease. 
Neuroscience 2009; 161: 1027–1036. 
 10 Eusebio A, Thevathasan W, Doyle Gaynor L, 
Pogosyan A, Bye E, Foltynie T, Zrinzo L, 
Ashkan K, Aziz T, Brown P: Deep brain stim-
ulation can suppress pathological synchro-
nisation in parkinsonian patients. J Neurol 
Neurosurg Psychiatry 2011; 82: 569–573. 
 11 Foffani G, Ardolino G, Egidi M, Caputo E, 
Bossi B, Priori A: Subthalamic oscillatory ac-
tivities at beta or higher frequency do not 
change after high-frequency DBS in Parkin-
son’s disease. Brain Res Bull 2006; 69: 123–
130. 
 12 Giannicola G, Marceglia S, Rossi L, Mrakic-
Sposta S, Rampini P, Tamma F, Cogiama-
nian F, Barbieri S, Priori A: The effects of 
levodopa and ongoing deep brain stimula-
tion on subthalamic beta oscillations in Par-
kinson’s disease. Exp Neurol 2010; 226: 120–
127. 
 13 Kuhn AA, Kempf F, Brucke C, Gaynor Doyle 
L, Martinez-Torres I, Pogosyan A, Trotten-
berg T, Kupsch A, Schneider GH, Hariz MI, 
Vandenberghe W, Nuttin B, Brown P: High-
frequency stimulation of the subthalamic 
nucleus suppresses oscillatory beta activity 
in patients with Parkinson’s disease in paral-
lel with improvement in motor performance. 
J Neurosci 2008; 28: 6165–6173. 
 14 Marceglia S, Rossi L, Foffani G, Bianchi A, 
Cerutti S, Priori A: Basal ganglia local field 
potentials: applications in the development 
of new deep brain stimulation devices for 
movement disorders. Expert Rev Med De-
vices 2007; 4: 605–614. 
 15 Priori A, Ardolino G, Marceglia S, Mrakic-
Sposta S, Locatelli M, Tamma F, Rossi L, Fof-
fani G: Low-frequency subthalamic oscilla-
tions increase after deep brain stimulation in 
Parkinson’s disease. Brain Res Bull 2006; 71: 
 149–154. 
 16 Rossi L, Marceglia S, Foffani G, Cogiama-
nian F, Tamma F, Rampini P, Barbieri S, 
Bracchi F, Priori A: Subthalamic local field 
potential oscillations during ongoing deep 
brain stimulation in Parkinson’s disease. 
Brain Res Bull 2008; 76: 512–521. 
 17 Bronte-Stewart H, Barberini C, Koop MM, 
Hill BC, Henderson JM, Wingeier B: The 
STN beta-band profile in Parkinson’s dis-
ease is stationary and shows prolonged at-
tenuation after deep brain stimulation. Exp 
Neurol 2009; 215: 20–28. 
 18 Brown P, Mazzone P, Oliviero A, Altibrandi 
MG, Pilato F, Tonali PA, Di Lazzaro V: Ef-
fects of stimulation of the subthalamic area 
on oscillatory pallidal activity in Parkinson’s 
disease. Exp Neurol 2004; 188: 480–490. 
 19 Silberstein P, Kuhn AA, Kupsch A, Trotten-
berg T, Krauss JK, Wohrle JC, Mazzone P,
Insola A, Di Lazzaro V, Oliviero A, Aziz T, 
Brown P: Patterning of globus pallidus local 
field potentials differs between Parkinson’s 
disease and dystonia. Brain 2003; 126: 2597–
2608. 
 20 Wingeier B, Tcheng T, Koop MM, Hill BC, 
Heit G, Bronte-Stewart HM: Intra-operative 
STN DBS attenuates the prominent beta 
rhythm in the STN in Parkinson’s disease. 
Exp Neurol 2006; 197: 244–251. 
 21 Rossi L, Foffani G, Marceglia S, Bracchi F, 
Barbieri S, Priori A: An electronic device for 
artefact suppression in human local field po-
tential recordings during deep brain stimu-
lation. J Neural Eng 2007; 4: 96–106. 
 22 Rosa M, Marceglia S, Servello D, Foffani G, 
Rossi L, Sassi M, Mrakic-Sposta S, Zangaglia 
R, Pacchetti C, Porta M, Priori A: Time-de-
pendent subthalamic local field potential 
changes after DBS surgery in Parkinson’s 
disease. Exp Neurol 2010; 222: 184–190. 
 23 LIMPE: Guidelines for the treatment of Par-
kinson’s disease. Neurol Sci 2003; 24:s203–
s204. 
 24 Marceglia S, Mrakic-Sposta S, Tommasi G, 
Bartolomei L, Foresti C, Valzania F, Galati S, 
Stefani A, Tamma F, Priori A: Multicenter 
study report: electrophysiological monitor-
ing procedures for subthalamic deep brain 
stimulation surgery in Parkinson’s disease. 
Neurol Sci 2010; 31: 449–457. 
 25 Egidi M, Rampini P, Locatelli M, Farabola 
M, Priori A, Pesenti A, Tamma F, Caputo E, 
Chiesa V, Villani RM: Visualisation of the 
subthalamic nucleus: a multiple sequential 
image fusion (MUSIF) technique for direct 
stereotaxic localisation and postoperative 
control. Neurol Sci 2002; 23(suppl 2):S71–
S72. 
 26 Welch P: The use of fast Fourier transform 
for the estimation of power spectra: a meth-
od based on time averaging over short, mod-
ified periodograms. IEEE Trans Acoust 
1967; 15: 70–73. 
 27 Chen G, Gupta A: Parametric Statistical 
Change Point Analysis. Boston, Birkhauser, 
2000. 
 28 Marceglia S, Foffani G, Bianchi AM, Baselli 
G, Tamma F, Egidi M, Priori A: Dopamine-
dependent non-linear correlation between 
subthalamic rhythms in Parkinson’s disease. 
J Physiol 2006; 571: 579–591. 
 29 Bergman H, Wichmann T, Karmon B, De-
Long MR: The primate subthalamic nucleus. 
II. Neuronal activity in the MPTP model of 
parkinsonism. J Neurophysiol 1994; 72: 507–
520. 
 30 Brown P, Oliviero A, Mazzone P, Insola A, 
Tonali P, Di Lazzaro V: Dopamine depen-
dency of oscillations between subthalamic 
nucleus and pallidum in Parkinson’s disease. 
J Neurosci 2001; 21: 1033–1038. 
 31 Levy R, Hutchison WD, Lozano AM, Dost-
rov sky JO: High-frequency synchronization 
of neuronal activity in the subthalamic nu-
cleus of parkinsonian patients with limb 
tremor. J Neurosci 2000; 20: 7766–7775. 
 32 Nini A, Feingold A, Slovin H, Bergman H: 
Neurons in the globus pallidus do not show 
correlated activity in the normal monkey, 
but phase-locked oscillations appear in the 
MPTP model of parkinsonism. J Neuro-
physiol 1995; 74: 1800–1805. 
 33 Raz A, Vaadia E, Bergman H: Firing patterns 
and correlations of spontaneous discharge of 
pallidal neurons in the normal and the trem-
ulous 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine vervet model of parkinsonism.
J Neurosci 2000; 20: 8559–8571. 
 34 Williams D, Tijssen M, Van Bruggen G, 
Bosch A, Insola A, Di Lazzaro V, Mazzone P, 
Oliviero A, Quartarone A, Speelman H, 
Brown P: Dopamine-dependent changes in 
the functional connectivity between basal 
ganglia and cerebral cortex in humans. Brain 
2002; 125: 1558–1569. 
D
ow
nl
oa
de
d 
by
: 
94
.1
67
.1
11
.1
2 
- 1
0/
29
/2
01
3 
3:
54
:2
9 
PM
 Rosa et al.  Neurosignals 2011;19:151–162 162
 35 Kuhn AA, Kupsch A, Schneider GH, Brown 
P: Reduction in subthalamic 8–35 Hz oscil-
latory activity correlates with clinical im-
provement in Parkinson’s disease. Eur J Neu-
rosci 2006; 23: 1956–1960. 
 36 Kuhn AA, Williams D, Kupsch A, Limousin 
P, Hariz M, Schneider GH, Yarrow K, Brown 
P: Event-related beta desynchronization in 
human subthalamic nucleus correlates with 
motor performance. Brain 2004; 127: 735–
746. 
 37 Brown P, Williams D: Basal ganglia local 
field potential activity: character and func-
tional significance in the human. Clin Neu-
rophysiol 2005; 116: 2510–2519. 
 38 Chen CC, Hsu YT, Chan HL, Chiou SM, Tu 
PH, Lee ST, Tsai CH, Lu CS, Brown P: Com-
plexity of subthalamic 13–35 Hz oscillatory 
activity directly correlates with clinical im-
pairment in patients with Parkinson’s dis-
ease. Exp Neurol 2010; 224: 234–240. 
 39 Hammond C, Bergman H, Brown P: Patho-
logical synchronization in Parkinson’s dis-
ease: networks, models and treatments. 
Trends Neurosci 2007; 30: 357–364. 
 40 Kuhn AA, Tsui A, Aziz T, Ray N, Brucke C, 
Kupsch A, Schneider GH, Brown P: Patho-
logical synchronisation in the subthalamic 
nucleus of patients with Parkinson’s disease 
relates to both bradykinesia and rigidity. Exp 
Neurol 2009; 215: 380–387. 
 41 Chen CC, Pogosyan A, Zrinzo LU, Tisch S, 
Limousin P, Ashkan K, Yousry T, Hariz MI, 
Brown P: Intra-operative recordings of local 
field potentials can help localize the subtha-
lamic nucleus in Parkinson’s disease surgery. 
Exp Neurol 2006; 198: 214–221. 
 42 Kuhn AA, Trottenberg T, Kivi A, Kupsch A, 
Schneider GH, Brown P: The relationship 
between local field potential and neuronal 
discharge in the subthalamic nucleus of pa-
tients with Parkinson’s disease. Exp Neurol 
2005; 194: 212–220. 
 43 Hamel W, Fietzek U, Morsnowski A, Schrad-
er B, Herzog J, Weinert D, Pfister G, Muller 
D, Volkmann J, Deuschl G, Mehdorn HM: 
Deep brain stimulation of the subthalamic 
nucleus in Parkinson’s disease: evaluation of 
active electrode contacts. J Neurol Neuro-
surg Psychiatry 2003; 74: 1036–1046. 
 44 Lanotte MM, Rizzone M, Bergamasco B, 
Faccani G, Melcarne A, Lopiano L: Deep 
brain stimulation of the subthalamic nucle-
us: anatomical, neurophysiological, and out-
come correlations with the effects of stimu-
lation. J Neurol Neurosurg Psychiatry 2002; 
 72: 53–58. 
 45 Zheng Z, Zhang Y, Li J, Zhang X, Zhuang P, 
Li Y: Subthalamic deep brain stimulation for 
Parkinson’s disease: correlation of active 
contacts and electrophysiologically mapped 
subthalamic nucleus. Chin Med J 2009; 122: 
 2419–2422. 
 46 Maks CB, Butson CR, Walter BL, Vitek JL, 
McIntyre CC: Deep brain stimulation acti-
vation volumes and their association with 
neurophysiological mapping and therapeu-
tic outcomes. J Neurol Neurosurg Psychiatry 
2009; 80: 659–666. 
 47 Saint-Cyr JA, Hoque T, Pereira LC, Dostrov-
sky JO, Hutchison WD, Mikulis DJ, Abosch 
A, Sime E, Lang AE, Lozano AM: Localiza-
tion of clinically effective stimulating elec-
trodes in the human subthalamic nucleus on 
magnetic resonance imaging. J Neurosurg 
2002; 97: 1152–1166. 
 48 Yoshida F, Martinez-Torres I, Pogosyan A, 
Holl E, Petersen E, Chen CC, Foltynie T, 
Limousin P, Zrinzo LU, Hariz MI, Brown P: 
Value of subthalamic nucleus local field po-
tentials recordings in predicting stimula-
tion parameters for deep brain stimulation 
in Parkinson’s disease. J Neurol Neurosurg 
Psychiatry 2010; 81: 885–889. 
 49 Moro E, Esselink RJ, Xie J, Hommel M, Ben-
abid AL, Pollak P: The impact on Parkinson’s 
disease of electrical parameter settings in 
STN stimulation. Neurology 2002; 59: 706–
713. 
 50 Deuschl G, Herzog J, Kleiner-Fisman G, 
Kubu C, Lozano AM, Lyons KE, Rodriguez-
Oroz MC, Tamma F, Troster AI, Vitek JL, 
Volkmann J, Voon V: Deep brain stimula-
tion: postoperative issues. Mov Disord 2006; 
 21(suppl 14):S219–S237. 
 51 Meissner W, Leblois A, Hansel D, Bioulac B, 
Gross CE, Benazzouz A, Boraud T: Subtha-
lamic high-frequency stimulation resets sub-
thalamic firing and reduces abnormal oscil-
lations. Brain 2005; 128: 2372–2382. 
 52 Benazzouz A, Piallat B, Pollak P, Benabid AL: 
Responses of substantia nigra pars reticulata 
and globus pallidus complex to high-fre-
quency stimulation of the subthalamic nu-
cleus in rats: electrophysiological data. Neu-
rosci Lett 1995; 189: 77–80. 
 53 Maurice N, Thierry AM, Glowinski J, De-
niau JM: Spontaneous and evoked activity of 
substantia nigra pars reticulata neurons dur-
ing high-frequency stimulation of the sub-
thalamic nucleus. J Neurosci 2003; 23: 9929–
9936. 
 54 Nimura T, Yamaguchi K, Ando T, Shibuya S, 
Oikawa T, Nakagawa A, Shirane R, Itoh M, 
Tominaga T: Attenuation of f luctuating stri-
atal synaptic dopamine levels in patients 
with Parkinson disease in response to sub-
thalamic nucleus stimulation: a positron 
emission tomography study. J Neurosurg 
2005; 103: 968–973. 
 55 Shon YM, Lee KH, Goerss SJ, Kim IY, Kim-
ble C, Van Gompel JJ, Bennet K, Blaha CD, 
Chang SY: High-frequency stimulation of 
the subthalamic nucleus evokes striatal do-
pamine release in a large animal model of 
human DBS neurosurgery. Neurosci Lett 
2010; 475: 136–140. 
 56 Foffani G, Priori A: Deep brain stimulation 
in Parkinson’s disease can mimic the 300-Hz 
subthalamic rhythm. Brain 2006; 129:e59–
e60. 
 57 Foffani G, Priori A, Egidi M, Rampini P, 
Tamma F, Caputo E, Moxon KA, Cerutti S, 
Barbieri S: 300-Hz subthalamic oscillations 
in Parkinson’s disease. Brain 2003; 126: 2153–
2163. 
 58 Hilker R, Voges J, Thiel A, Ghaemi M, Her-
holz K, Sturm V, Heiss WD: Deep brain stim-
ulation of the subthalamic nucleus versus
levodopa challenge in Parkinson’s disease: 
measuring the on- and off-conditions with 
FDG-PET. J Neural Transm 2002; 109: 1257–
1264. 
 59 Baudrexel S, Witte T, Seifried C, von Wegner 
F, Beissner F, Klein J, Steinmetz H, Deich-
mann R, Roeper J, Hilker R: Resting state 
FMRI reveals increased subthalamic nucle-
us-motor cortex connectivity in Parkinson’s 
disease. Neuroimage 2011;55:1728–1738. 
 60 Dorval AD, Russo GS, Hashimoto T, Xu W, 
Grill WM, Vitek JL: Deep brain stimulation 
reduces neuronal entropy in the MPTP-pri-
mate model of Parkinson’s disease. J Neuro-
physiol 2008; 100: 2807–2818. 
 61 Hammond C, Ammari R, Bioulac B, Garcia 
L: Latest view on the mechanism of action of 
deep brain stimulation. Mov Disord 2008; 23: 
 2111–2121. 
 62 Montgomery EB Jr, Gale JT: Mechanisms of 
action of deep brain stimulation. Neurosci 
Biobehav Rev 2008; 32: 388–407. 
 
D
ow
nl
oa
de
d 
by
: 
94
.1
67
.1
11
.1
2 
- 1
0/
29
/2
01
3 
3:
54
:2
9 
PM
